Co-Prescription Trends in a Large Cohort of Subjects Predict Substantial Drug-Drug Interactions

• Jeffrey J. Sutherland ,

  * E-mail: sutherlandje@lilly.com (JJS); tim@thinksano.com (TPR)

  Affiliation Lilly Research Labs IT, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Thomas M. Daly,

  Affiliation Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Xiong Liu,

  Affiliation Lilly Research Labs IT, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Keith Goldstein,

  Affiliation Drug Disposition and Toxicology, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Joseph A. Johnston,

  Affiliation Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, United States of America

  ⨯
• Timothy P. Ryan

  * E-mail: sutherlandje@lilly.com (JJS); tim@thinksano.com (TPR)

  Affiliation Sano Informed Prescribing, Brentwood, Tennessee, United States of America

  ⨯